BR112020014719A2 - Tratamento de hipoglicemia pós-bariátrica usando glucagon estável em minidose - Google Patents
Tratamento de hipoglicemia pós-bariátrica usando glucagon estável em minidose Download PDFInfo
- Publication number
- BR112020014719A2 BR112020014719A2 BR112020014719-2A BR112020014719A BR112020014719A2 BR 112020014719 A2 BR112020014719 A2 BR 112020014719A2 BR 112020014719 A BR112020014719 A BR 112020014719A BR 112020014719 A2 BR112020014719 A2 BR 112020014719A2
- Authority
- BR
- Brazil
- Prior art keywords
- glucagon
- analog
- fact
- aprotic solvent
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620861P | 2018-01-23 | 2018-01-23 | |
| US62/620,861 | 2018-01-23 | ||
| PCT/US2019/014815 WO2019147718A1 (en) | 2018-01-23 | 2019-01-23 | Treatment of post-bariatric hypoglycemia using mini-dose stable glucagon |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020014719A2 true BR112020014719A2 (pt) | 2020-12-08 |
Family
ID=65352189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020014719-2A BR112020014719A2 (pt) | 2018-01-23 | 2019-01-23 | Tratamento de hipoglicemia pós-bariátrica usando glucagon estável em minidose |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210030847A1 (https=) |
| EP (1) | EP3743097A1 (https=) |
| JP (1) | JP7444786B2 (https=) |
| KR (1) | KR20200134213A (https=) |
| CN (1) | CN111936159A (https=) |
| AU (1) | AU2019211352A1 (https=) |
| BR (1) | BR112020014719A2 (https=) |
| MX (1) | MX2020007768A (https=) |
| WO (1) | WO2019147718A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018026899A1 (en) * | 2016-08-03 | 2018-02-08 | Joslin Diabetes Center, Inc. | Methods and compositions for treating hypoglycemia |
| US12543982B2 (en) | 2021-01-22 | 2026-02-10 | Cilag Gmbh International | Method of adjusting a surgical parameter based on biomarker measurements |
| US12569203B2 (en) * | 2021-01-22 | 2026-03-10 | Cilag Gmbh International | Bariatric surgery post-surgical monitoring |
| US12527515B2 (en) | 2021-01-22 | 2026-01-20 | Cilag Gmbh International | Colorectal surgery post-surgical monitoring |
| US12128089B2 (en) * | 2022-05-26 | 2024-10-29 | Slayback Pharma Llc | Stable liquid compositions of glucagon |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2552952A1 (en) | 2010-03-26 | 2013-02-06 | Novo Nordisk A/S | Novel glucagon analogues |
| EP2683364B1 (en) | 2011-03-10 | 2017-01-18 | Xeris Pharmaceuticals, Inc. | Stable formulations for parenteral injection of peptide drugs |
| JP2014510739A (ja) * | 2011-03-28 | 2014-05-01 | ノヴォ ノルディスク アー／エス | 新規のグルカゴン類似体 |
| AU2013295035B2 (en) * | 2012-07-23 | 2017-08-03 | Zealand Pharma A/S | Glucagon analogues |
| DK3102184T3 (da) | 2014-02-06 | 2019-05-06 | Xeris Pharmaceuticals Inc | Stabile formuleringer af peptider og fremgangsmåder til fremstilling |
| MY185334A (en) * | 2014-12-30 | 2021-05-06 | Hanmi Pharm Ind Co Ltd | Glucagon derivatives with improved stability |
| AU2016267052B2 (en) * | 2015-05-22 | 2022-01-20 | The Bot Of The Leland Stanford Junior University | Treatment of post-bariatric hypoglycemia with GLP-1 antagonists |
| WO2016196976A1 (en) * | 2015-06-04 | 2016-12-08 | Xeris Pharmaceuticals, Inc. | Glucagon delivery apparatuses and related methods |
| US9649364B2 (en) | 2015-09-25 | 2017-05-16 | Xeris Pharmaceuticals, Inc. | Methods for producing stable therapeutic formulations in aprotic polar solvents |
| AU2016304588A1 (en) * | 2015-08-06 | 2018-02-15 | Xoma (Us) Llc | Antibody fragments against the insulin receptor and uses thereof to treat hypoglycemia |
| GB201710822D0 (en) * | 2017-07-05 | 2017-08-16 | Zealand Pharma As | Methods and medical uses relating to the treatment of hypoglycaemia |
-
2019
- 2019-01-23 BR BR112020014719-2A patent/BR112020014719A2/pt not_active IP Right Cessation
- 2019-01-23 US US16/964,124 patent/US20210030847A1/en not_active Abandoned
- 2019-01-23 JP JP2020561591A patent/JP7444786B2/ja active Active
- 2019-01-23 KR KR1020207022613A patent/KR20200134213A/ko not_active Ceased
- 2019-01-23 CN CN201980009791.5A patent/CN111936159A/zh active Pending
- 2019-01-23 MX MX2020007768A patent/MX2020007768A/es unknown
- 2019-01-23 WO PCT/US2019/014815 patent/WO2019147718A1/en not_active Ceased
- 2019-01-23 AU AU2019211352A patent/AU2019211352A1/en not_active Abandoned
- 2019-01-23 EP EP19704169.2A patent/EP3743097A1/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021511386A (ja) | 2021-05-06 |
| MX2020007768A (es) | 2020-11-12 |
| WO2019147718A8 (en) | 2020-08-06 |
| AU2019211352A1 (en) | 2020-07-30 |
| EP3743097A1 (en) | 2020-12-02 |
| KR20200134213A (ko) | 2020-12-01 |
| WO2019147718A1 (en) | 2019-08-01 |
| US20210030847A1 (en) | 2021-02-04 |
| CN111936159A (zh) | 2020-11-13 |
| JP7444786B2 (ja) | 2024-03-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240207365A1 (en) | Methods for producing stable therapeutic formulations in aprotic polar solvents | |
| JP6763777B2 (ja) | 安定なペプチド製剤、および調製のための方法 | |
| JP7444786B2 (ja) | 低用量の安定なグルカゴンを使用する肥満治療手術後の低血糖症の処置 | |
| Hawkes et al. | Novel preparations of glucagon for the prevention and treatment of hypoglycemia | |
| Beato-Víbora et al. | New uses and formulations of glucagon for hypoglycaemia | |
| US12514907B2 (en) | Treatment of exercise-induced hypoglycemia in type 1 and insulin using type 2 diabetes | |
| WO2016196976A1 (en) | Glucagon delivery apparatuses and related methods | |
| US20240238381A1 (en) | Stable sustained release therapeutic compositions in aprotic polar solvents and methods of manufacturing the same | |
| US11590205B2 (en) | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents | |
| BR112020000447A2 (pt) | métodos de tratamento de hiperinsulinismo congênito | |
| HK40101667A (en) | Methods for producing stable therapeutic formulations in aprotic polar solvents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 4A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2706 DE 16-11-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |